Authorities in India have revoked a patent on GlaxoSmithKline's breast cancer drug Tykerb,in the latest blow to big pharma in terms of intellectual property.
The country's Intellectual Property Appellate Board upheld a GSK patent granted on the active pharmaceutical ingredient in Tykerb, lapatinib, citing innovative merit. However Tykerb is the salt form of lapatinib and the board decided it represents an incremental innovation, so patent protection for the drug has been pulled.
http://www.pharmatimes.com/Article/13-08-02/India_revokes_patent_on_GSK_s_Tykerb.aspx?
The country's Intellectual Property Appellate Board upheld a GSK patent granted on the active pharmaceutical ingredient in Tykerb, lapatinib, citing innovative merit. However Tykerb is the salt form of lapatinib and the board decided it represents an incremental innovation, so patent protection for the drug has been pulled.
http://www.pharmatimes.com/Article/13-08-02/India_revokes_patent_on_GSK_s_Tykerb.aspx?
No comments:
Post a Comment